Novo's NovoSeven Posts $19 Mil. In U.S. Sales Since April Launch
Executive Summary
Novo Nordisk's hemophilia treatment NovoSeven (recombinant Factor VIIa) generated U.S. sales of approximately $19 mil. in its first three months on the U.S. market, Novo indicated in an Aug. 11 statement on half-year financial results. Novo began marketing the product in the U.S. in April.
You may also be interested in...
Novo Nordisk Demerger Expected To Aid External Collaborations
Novo expects the demerger of its healthcare and enzyme businesses in January 2001 to enhance possibilities for collaborations with other companies.
Novo Nordisk Demerger Expected To Aid External Collaborations
Novo expects the demerger of its healthcare and enzyme businesses in January 2001 to enhance possibilities for collaborations with other companies.
Takeda/Lilly Actos Approved With Broader Combo Use Than Other Glitazones
Takeda/Lilly's antidiabetic Actos will be launched in August with broader combination use than SmithKline Beecham/Bristol-Myers Squibb's "glitazone" agent Avandia.